Pulmatrix nabs accelerated review status in U.S. for itraconazole

The FDA has granted Fast Track status to Pulmatrix’s (PULM +2.7%) inhaled itraconazole for the treatment of allergic bronchopulmonary aspergillosis in asthma patients.

A Phase 2 study is in process with topline results expected by year-end.

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3536365-pulmatrix-nabs-accelerated-review-status-in-u-s-for-itraconazole